The AIM-listed company, which provides specialist services to the pharmaceutical industry, said it had appointed Dr Michael Forstner as head of risk management and pharmacoepidemiology.
The group added that the ongoing contracts of Mesama Consulting, a Swiss-based consultancy founded in 2011 by Professor Jan-Willem van der Velden and most recently owned and managed by Forstner, would be assigned to PrimeVigilance.
Ergomed said Frostner is an expert in pharmacovigilance with significant experience in the planning, development, implementation and evaluation of risk management strategies, including post-authorisation studies, supporting the safe use of medicinal products.
They added that his skills would broaden Ergomed's premium service offering within PrimeVigilance, and build new revenue streams in pharmacoepidemiology and risk minimisation services, meeting high demand.
Stephen Stamp, Ergomed chief executive, said: "I am delighted to welcome Michael to Ergomed with his significant experience in PV services, in addition to his unique expertise in pharmacoepidemiology and risk management strategies.
He added: “His appointment will add value to our PrimeVigilance services as well as providing a bridge between CRO and PV, which fits perfectly in our strategy to leverage our expertise in pharmacovigilance and late phase clinical research, and build a new revenue stream in both our PV and specialist CRO services. We remain focused on growing both of our service offerings organically and through strategic acquisitions."
In mid-morning trading Friday, Ergomed shares were up 2.6% at 235p.
--Adds share price--